Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:

NCT ID: NCT04999072 Active, not recruiting - Colorectal Cancer Clinical Trials

Carbohydrate Antigen 19-9 in Colorectal Cancer

Start date: April 19, 2020
Phase:
Study type: Observational

4,972 patients who underwent surgery for primary CRC between January 2004 and December 2015 at Seoul National University Hospital were retrospectively reviewed. CA19-9 is a valuable prognostic and diagnostic marker for CRC when used adjunctively with CEA and can be a supplementary marker with CEA to improve sensitivity, especially with elevated preoperative CA19-9.

NCT ID: NCT04963283 Active, not recruiting - Colorectal Cancer Clinical Trials

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Start date: June 23, 2021
Phase: Phase 2
Study type: Interventional

Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with nivolumab have led to this concept for a clinical trial to combine cabozantinib and nivolumab in patients with metastatic MSS CRC in the third line setting and beyond.

NCT ID: NCT04913337 Active, not recruiting - Breast Cancer Clinical Trials

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Start date: June 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT ID: NCT04902872 Active, not recruiting - Breast Cancer Clinical Trials

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Start date: May 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.

NCT ID: NCT04878185 Active, not recruiting - Colorectal Cancer Clinical Trials

Optimizing Physical Function Before Cancer Surgery in Older People at Risk

CanOptiPhys
Start date: May 10, 2021
Phase: N/A
Study type: Interventional

This randomized controlled trial is a multicentre study designed to explore the effects of preoperative exercise on physical fitness, postoperative complications, recovery, and health-related quality of life in older individuals at risk scheduled to undergo colorectal cancer surgery. The hypothesis is that older patients with low preoperative physical capacity will benefit from preoperative exercise in terms of lower risk for postoperative complications and improved recovery after surgery.

NCT ID: NCT04868773 Active, not recruiting - Colorectal Cancer Clinical Trials

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Start date: July 16, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).

NCT ID: NCT04853017 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

AMPLIFY-201
Start date: October 4, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

NCT ID: NCT04780217 Active, not recruiting - Colorectal Cancer Clinical Trials

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Start date: August 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors

NCT ID: NCT04761783 Active, not recruiting - Colorectal Cancer Clinical Trials

BESPOKE Study of ctDNA Guided Immunotherapy

Start date: May 28, 2021
Phase:
Study type: Observational

This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA™ test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA™ results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.

NCT ID: NCT04745754 Active, not recruiting - Breast Cancer Clinical Trials

The Engaging Primary Care in Cancer Survivorship (EPICS) Study

EPICS
Start date: September 21, 2021
Phase: N/A
Study type: Interventional

A quasi-experimental non-randomized pre/post with control group trial of two models of cancer survivorship care in early-stage colorectal and breast cancer survivors cared for in a community-based, integrated health care setting.